• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

    4/9/24 4:05:00 PM ET
    $ILMN
    $SMMT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ILMN alert in real time by email

    Joydeep Goswami to serve as advisor through June 30

    Illumina reaffirms Q1 2024 and full-year 2024 financial guidance

    SAN DIEGO, April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments.

    Ankur Dhingra, who will become Illumina's Chief Financial Officer on April 15.

    Ankur Dhingra is joining Illumina as Chief Financial Officer (CFO), leading Illumina's financial planning and analysis, accounting, investor relations, internal audit, tax, and treasury functions. Dhingra brings a breadth of experience from the life sciences tools, diagnostics, and pharmaceutical industries. He formerly was CFO at Summit Therapeutics Inc. (NASDAQ:SMMT), and prior to that was CFO of CAREDx, Inc. Dhingra spent more than 18 years at Agilent Technologies, most recently as VP, Investor Relations. Before that, he held various finance leadership roles with progressively increasing responsibility, including multiple business unit CFO roles. He brings experience in developing and executing growth and margin improvement strategies, delivering P&L commitments, and driving businesses toward increasing levels of performance. Dhingra has a demonstrated record of success in executing and influencing growth-oriented business strategies, as well as managing global finance and accounting teams. He is a Chartered Accountant and member of The Institute of Chartered Accountants of India.

    Jakob Wedel has been named Chief Strategy and Corporate Development Officer. Wedel joined Illumina in November 2023 as CEO Chief of Staff, leading strategic transformation initiatives. In his new role, Wedel is responsible for driving Illumina's strategic planning, partnerships, and acquisitions. Previously, Wedel was partner at EY's strategy practice, co-leading their global life science practice, and served in roles at McKinsey & Company and Bain & Company. In the early 2000s, Wedel co-founded the Nordic strategy firm QVARTZ, which was later acquired by Bain.

    "I am proud of the talent joining our management team as we work to deliver on Illumina's mission to improve human health by unlocking the power of the genome," said Jacob Thaysen, Illumina CEO. "Ankur brings deep financial expertise, investor and leadership experience, and industry knowledge to Illumina's CFO role, and Jakob has keen insights gained from 25 years in strategy leadership roles with global consulting firms. Both are deeply committed to serving our customers and helping Illumina grow."

    Dhingra and Wedel are both relocating to San Diego. They succeed Goswami, who held both the CFO and Chief Strategy and Corporate Development Officer roles since early 2023. Goswami joined Illumina in 2019 to lead strategy and corporate development. He will continue as an advisor to the company starting April 15 and through June 30. He departs the organization on July 1.

    "We are grateful to Joydeep for his many contributions to Illumina over more than four years, and for most recently leading these two key functions," said Thaysen. "Joydeep will continue with us for several weeks to support a smooth leadership transition."

    The company has reaffirmed its guidance for the first quarter 2024 and full-year 2024, as announced during its fourth quarter 2023 earnings call on February 8, 2024.

    About Illumina

    Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

    Contacts

    Investors:

    Salli Schwartz

    858-291-6421

    [email protected]

    Media:

    David McAlpine

    347-327-1336

    [email protected]

    Jakob Wedel, who will become Illumina's Chief Strategy and Corporate Development Officer on April 15.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-appoints-ankur-dhingra-chief-financial-officer-jakob-wedel-chief-strategy-and-corporate-development-officer-302112206.html

    SOURCE Illumina, Inc.

    Get the next $ILMN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ILMN
    $SMMT

    CompanyDatePrice TargetRatingAnalyst
    Summit Therapeutics Inc.
    $SMMT
    9/17/2025$13.00Underweight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    9/4/2025$40.00Buy
    Guggenheim
    Summit Therapeutics Inc.
    $SMMT
    8/19/2025$21.00Neutral
    Piper Sandler
    Illumina Inc.
    $ILMN
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    Illumina Inc.
    $ILMN
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    Summit Therapeutics Inc.
    $SMMT
    7/1/2025$30.00Buy
    UBS
    Summit Therapeutics Inc.
    $SMMT
    6/11/2025$12.00Underperform
    Leerink Partners
    Summit Therapeutics Inc.
    $SMMT
    3/26/2025$23.00 → $35.00Neutral → Buy
    Citigroup
    More analyst ratings

    $ILMN
    $SMMT
    SEC Filings

    View All

    Summit Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    9/8/25 7:45:14 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    8/11/25 5:13:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Summit Therapeutics Inc.

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    8/11/25 4:51:33 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 65,750 shares of common stock. Awards were made to eight new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on September 18, 2025. The options have a ten (10) year term and an exercise price of $19.23 per share, the closing price per share of the Company's common stock as reported by Nasdaq on

    9/24/25 4:30:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

    Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be featured as part of the Presidential Symposium at the European Society for Medic

    9/24/25 7:00:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Illumina advances personalized cancer care with new pharma development partnerships

    Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker SAN DIEGO, Sept. 23, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ:ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight™ Oncology (TSO) Comprehensive genomic profiling test. The continued expansion of tumor-agnostic CDx claims underscores Illumina's commitment to advance access for patients to precision oncology care by generating standardized, globally distributable tests. The new companion diagnostic partnerships will focus on KRAS alterations, which are known to cause uncontrolled cell growth, leading to cancer.

    9/23/25 9:15:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Summit Therapeutics with a new price target

    Barclays initiated coverage of Summit Therapeutics with a rating of Underweight and set a new price target of $13.00

    9/17/25 8:03:56 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Summit Therapeutics with a new price target

    Guggenheim initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $40.00

    9/4/25 9:07:53 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Summit Therapeutics with a new price target

    Piper Sandler initiated coverage of Summit Therapeutics with a rating of Neutral and set a new price target of $21.00

    8/19/25 8:35:55 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Zanganeh Mahkam bought $5,984,756 worth of shares (338,394 units at $17.69) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/11/25 7:36:31 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $5,984,756 worth of shares (338,394 units at $17.69), increasing direct ownership by 0.06% to 556,093,090 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/11/25 7:32:04 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:20:13 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/19/25 4:45:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Zanganeh Mahkam bought $5,984,756 worth of shares (338,394 units at $17.69) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/11/25 7:36:31 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $5,984,756 worth of shares (338,394 units at $17.69), increasing direct ownership by 0.06% to 556,093,090 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    9/11/25 7:32:04 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Financials

    Live finance-specific insights

    View All

    Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

    With Longer-Term Follow-Up of Western Patients, Ivonescimab Plus Chemotherapy Demonstrated Improving Global OS Trend with Nominal p-value of 0.0332 vs. Chemotherapy Alone; North American Patients' OS HR=0.70 Consistent Median Overall Survival Observed in Western, Asian Patients in Longer-Term Follow-Up Analysis of Western Patients Presented at Presidential Symposium at WCLC 2025 Conference Call to be Held at 8:00am ET on Monday, September 8, 2025 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was prese

    9/7/25 3:30:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

    Ivonescimab in Combination with Chemotherapy Showed Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy; Positive Trend Observed in Overall Survival Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China; Ivonescimab Monotherapy Approved by NMPA in China for 1L PD-L1 Positive Advanced NSCLC Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant, Clinically Mea

    8/11/25 5:03:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

    Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basisGAAP operating margin of 20.2% and non-GAAP operating margin of 23.8% for Q2 2025GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19 for Q2 2025Cash provided by operations of $234 million and free cash flow of $204 million for Q2 2025For fiscal year 2025, we now expect:Total company constant currency revenue decline in the range of (2.5%) to (0.5%), up from (3%) to (1%) previouslyNon-GAAP operating margin of approximately 22% - 22.5%, up from 21.5% - 22.0% previouslyNon-GAAP diluted EPS in the range of $4.45 - $4.55, an increase from our May guidance of $4.20 - $4.30. This include

    7/31/25 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    Leadership Updates

    Live Leadership Updates

    View All

    Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

    Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.

    9/18/25 9:15:00 AM ET
    $ALNY
    $ILMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

    POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. ("BioStem" or the "Company") (OTC:BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief Financial Officer (CFO). Mr. Poe has served on BioStem's Board of Directors since 2022. Michael Fortunato, the Company's prior CFO, has assumed the role of Chief Accounting Officer. "I'm excited to welcome Brandon as CFO during this pivotal period of growth and innovation for BioStem," said Jason Matuszewski, Chairman and CEO. "Brandon brings proven financial leader

    8/14/25 4:01:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

    Stephen MacMillan to retire from the Board SAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Hologic, who joined the Illumina Board in June 2023, has decided to retire from the board in preparation for the company

    3/25/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care